Drugs Affecting Hemostasis: Potential pharmacodynamic interaction (increased risk of bleeding) when enoxaparin is used with drugs inhibiting coagulation (e.g., anticoagulants, platelet aggregation inhibitors [e.g., salicylates or other nonsteroidal anti-inflammatory agents, dipyridamole, sulfinpyrazone]). Such drugs should be discontinued prior to initiating enoxaparin therapy since concomitant use of enoxaparin with these agents may increase the risk of hemorrhage. If concomitant use of enoxaparin and drugs that affect hemostasis is considered essential, careful clinical and laboratory monitoring is advised.